Previous close | 394.30 |
Open | 391.30 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 389.00 - 392.75 |
52-week range | 260.25 - 470.50 |
Volume | |
Avg. volume | 832 |
Market cap | 25.906B |
Beta (5Y monthly) | 0.66 |
PE ratio (TTM) | 33.55 |
EPS (TTM) | 11.71 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 481.51 |
Company Announcement Net sales of DARZALEX® in 2022 totaled USD 7,977 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 7,977 millio
GILD vs. GMAB: Which Stock Is the Better Value Option?
Company Announcement COPENHAGEN, Denmark; January 19, 2023 – Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023 regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported that member of the Board of Directors, Mijke Zachariasse, acquired a total of 175 shares in Genmab A/S due to vesting of restricted stock units (partly as employee of Genmab B.V., partly as board member). The corr